Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
North America Canada Cost Effectiveness

Canada Pulls Controversial Pricing Measures

  • News

Executive Summary

Some measures aimed at reducing medicine prices in Canada have been dropped, to the relief of the pharmaceutical industry.

You may also be interested in...



Canadian Guideline Homes In On Excessive Medicine Pricing

New draft guidelines outlining how Canada’s drug pricing authority will decide whether to investigate if a medicine is excessively priced are now out for consultation.

'Status Quo' Interim Pricing Guidance Now In Force In Canada

Provisional guidance on controversial pricing reforms is now in place in Canada.

Canada Says Reference Price Changes Could Save Payers Billions

Changes to Canada’s reference pricing system kick in on 1 July and could save billions.

Table

View full table

Related Content

Generics Bulletin
Pink Sheet
Pink Sheet

Topics

Tags:
North America Canada Cost Effectiveness
Latest News

Clinical Trial Diversity Would Benefit From Regulatory, Financial Incentives, Experts Say

Could US FDA Move Gene Therapy Regulation To Device Center In Years To Come?

Standardization Of Patient-Focused Core Clinical Outcomes Could Enable Labeling Comparisons

US Bill Seeks To Eliminate Biosimilar Interchangeability Trial Burden

See All
UsernamePublicRestriction

Register

PS146117

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By